Skip to main content
BCAB
NASDAQ Life Sciences

BioAtla to Reconvene Reverse Stock Split Vote; CEO Granted Super-Voting Share to Ensure Approval

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$0.317
Mkt Cap
$18.708M
52W Low
$0.24
52W High
$1.43
52W Position info
32% above low
Off High info
78% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

BCAB sits 32% above its 52-week low of $0.24.

Summary

BioAtla, Inc. will reconvene a special meeting to vote on a reverse stock split, with its CEO granted a super-voting share to facilitate approval after a previous attempt failed to secure the necessary votes. This action is critical for maintaining Nasdaq listing compliance.


Key Events · Corporate Governance and Compliance · BCAB

  • Special Meeting Reconvened for Reverse Stock Split

    BioAtla, Inc. will reconvene its special meeting on January 26, 2026, to vote on a reverse stock split proposal with a ratio ranging from 1-for-5 to 1-for-20.

  • CEO Granted Super-Voting Share to Ensure Approval

    The Board issued a Series A Junior Preferred Stock (Super-Voting Share) to CEO Jay M. Short, granting him votes equal to all outstanding common stock for the reverse split proposal. This measure was taken after a previous attempt to pass the split failed to secure the required two-thirds approval, and the Super-Voting Share is designed to ensure the split passes if common stockholders approve it.

  • Critical for Nasdaq Listing Compliance

    The reverse stock split is likely a critical step for the company to maintain compliance with Nasdaq's minimum bid price requirements, given its current stock price of $0.3169.

  • Prior Dilutive Financing Approved

    Stockholders previously approved the potential issuance of 20% or more of common stock related to pre-paid advance agreements and a standby equity purchase agreement, indicating recent capital raising efforts.


Analysis · BCAB · Life Sciences

This DEFA14A filing reveals BioAtla's urgent efforts to implement a reverse stock split, ranging from 1-for-5 to 1-for-20, likely to regain Nasdaq listing compliance given its low share price. After failing to secure the necessary two-thirds shareholder vote in a previous attempt, the Board has taken the extraordinary step of issuing a "Super-Voting Share" to CEO Jay M. Short. While this share is structured to reflect the common stock vote on the reverse split, its issuance is a significant corporate governance event, highlighting the Board's determination to pass the proposal. Investors should consider the implications of such a measure on shareholder democracy and the underlying financial pressures necessitating these actions.

At the time of this filing, BCAB was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $0.24 to $1.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BCAB - Latest Insights

BCAB
Jun 03, 2026, 4:07 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $3.40
Real-time Price: $4.35 info
Change: +$0.950 (+28%) info
Market Cap: $6.779M info
BCAB
May 15, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.27
Real-time Price: $4.35 info
Change: +$0.080 (+2%) info
Market Cap: $6.779M info
BCAB
May 15, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.27
Real-time Price: $4.35 info
Change: +$0.080 (+2%) info
Market Cap: $6.779M info
BCAB
Apr 02, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.1292
Real-time Price: $4.35 info
Change: +$4.22 (+3,267%) info
Market Cap: $6.779M info
BCAB
Apr 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1333
Real-time Price: $4.35 info
Change: +$4.22 (+3,163%) info
Market Cap: $6.779M info
BCAB
Mar 31, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
10
Price at Filing: $0.1306
Real-time Price: $4.35 info
Change: +$4.22 (+3,231%) info
Market Cap: $6.779M info
BCAB
Mar 31, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1306
Real-time Price: $4.35 info
Change: +$4.22 (+3,231%) info
Market Cap: $6.779M info
BCAB
Mar 23, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1749
Real-time Price: $4.35 info
Change: +$4.18 (+2,387%) info
Market Cap: $6.779M info
BCAB
Mar 02, 2026, 7:42 AM EST
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $0.2316
Real-time Price: $4.35 info
Change: +$4.12 (+1,778%) info
Market Cap: $6.779M info
BCAB
Mar 02, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2316
Real-time Price: $4.35 info
Change: +$4.12 (+1,778%) info
Market Cap: $6.779M info